BMS to build $2.3 B Houston plant as MHRA clears Lilly's weight-loss drug; IMDRF issues PCCP guidance

Bristol Myers Squibb announced a plan to invest about $2.3 billion in a new manufacturing facility in Houston. The site is expected to expand the company’s production capacity for its pipeline and existing products.

The UK Medicines and Healthcare products Regulatory Agency gave approval to Eli Lilly's new weight‑loss medication, indicating it can also be used to treat type 2 diabetes. The decision adds another option for patients seeking metabolic disease management.

Separately, the International Medical Device Regulators Forum released a technical document outlining principles for regulators to adopt predetermined change control plans (PCCPs). The guidance lists key elements manufacturers should include in their PCCPs and aims to harmonize regulatory approaches worldwide.